Results 181 to 190 of about 18,093 (237)
Current use of neuromuscular blocking agents and antagonists in Korea: a 2018 survey. [PDF]
Anesth Pain Med (Seoul), 2019 Kim JS +8 more
europepmc +1 more source
Current Use of Neuromuscular Blocking Agents in Intensive Care Units. [PDF]
Turk J Anaesthesiol Reanim, 2019 Tezcan B, Turan S, Özgök A.
europepmc +1 more source
Neuromuscular blocking agents for acute respiratory distress syndrome. [PDF]
J Crit Care, 2019 Torbic H, Duggal A.
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
American Journal of Nursing, 1997
O nene afternoon at her 150bed community hospital, Marcia Czabo, RN, a new nurse manager for the intensive care unit, was conducting a quality improvement survey of stock medications in the medication room. She quickly made two alarming discoveries: She found pancuronium located in the stock box where heparin flush solutions should have been, and ...
L L, Lilley, R, Guanci
openaire +2 more sources
O nene afternoon at her 150bed community hospital, Marcia Czabo, RN, a new nurse manager for the intensive care unit, was conducting a quality improvement survey of stock medications in the medication room. She quickly made two alarming discoveries: She found pancuronium located in the stock box where heparin flush solutions should have been, and ...
L L, Lilley, R, Guanci
openaire +2 more sources
The future of neuromuscular blocking agents
Current Opinion in Anaesthesiology, 2020Purpose of review The present review provides a summary of the literature on recent development of new neuromuscular blocking agents and presents clinically well established and new reversal agents. Recent findings Anesthesiologists are still waiting for the ideal neuromuscular ...
Christiane G, Stäuble, Manfred, Blobner
openaire +2 more sources
International Anesthesiology Clinics, 1988
Clearly, many aspects of the action of neuromuscular blockers remain poorly understood at the molecular level. In the case of competitive blockers, blockade of EPPs by competitive binding to the ACh receptor site accounts for the most clinically important aspect of blockade.
C J, Lingle, J H, Steinbach
openaire +2 more sources
Clearly, many aspects of the action of neuromuscular blockers remain poorly understood at the molecular level. In the case of competitive blockers, blockade of EPPs by competitive binding to the ACh receptor site accounts for the most clinically important aspect of blockade.
C J, Lingle, J H, Steinbach
openaire +2 more sources